Clinical Trial Update: Karenitecin in Treating Patients With Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating Karenitecin in patients with recurrent malignant glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Karenitecin

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED